Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.

Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F, Girard PM; Narval Trial Group.

AIDS. 2002 Mar 29;16(5):727-36.

PMID:
11964529
2.

Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vézinet F, Peytavin G, Costagliola D, Girard PM; Narval Trial Group.

Antivir Ther. 2003 Oct;8(5):427-34.

PMID:
14640390
3.

Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.

Clevenbergh P, Durant J, Halfon P, del Giudice P, Mondain V, Montagne N, Schapiro JM, Boucher CA, Dellamonica P.

Antivir Ther. 2000 Mar;5(1):65-70.

PMID:
10846595
4.

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR, Graham NM; VIRA3001 Study Team.

AIDS. 2002 Mar 8;16(4):579-88.

PMID:
11873001
5.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
6.

Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).

Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, Le Camus C, Saux MC, Fleury HJ, Pellegrin JL.

AIDS. 2002 Jul 5;16(10):1331-40.

PMID:
12131209
7.

Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.

Haupts S, Ledergerber B, Böni J, Schüpbach J, Kronenberg A, Opravil M, Flepp M, Speck RF, Grube C, Rentsch K, Weber R, Günthard HF; Swiss HIV Cohort Study.

Antivir Ther. 2003 Oct;8(5):443-54.

PMID:
14640392
8.

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC.

AIDS. 2000 Jun 16;14(9):F83-93.

PMID:
10894268
9.

Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen).

Saracino A, Monno L, Locaputo S, Torti C, Scudeller L, Ladisa N, Antinori A, Sighinolfi L, Chirianni A, Mazzotta F, Carosi G, Angarano G.

J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1587-98.

PMID:
15577415
10.

A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575.

Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Tilles JG, Forthal DN, Leedom J, Leibowitz M, McCutchan JA, Richman DD; California Collaborative Treatment Group.

AIDS. 2005 Feb 18;19(3):295-302.

PMID:
15718840
11.

No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.

Ghosn J, Wirden M, Ktorza N, Peytavin G, Aït-Mohand H, Schneider L, Dominguez S, Bricaire F, Calvez V, Costagliola D, Katlama C.

AIDS. 2005 Oct 14;19(15):1643-7.

PMID:
16184034
12.

Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.

Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, Sax H, Perneger TV, Perrin L, Kaiser L, Yerly S.

AIDS. 1999 Feb 4;13(2):F17-21.

PMID:
10202819
13.

Phenotypic testing predicts virological response in successive protease inhibitor-based regimens.

Pérez-Elías MJ, Lanier R, Muñoz V, Garcia-Arata I, Casado JL, Marti-Belda P, Moreno A, Dronda F, Antela A, Marco S, Moreno S.

AIDS. 2000 Jun 16;14(9):F95-101.

PMID:
10894269
14.

A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).

Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M.

AIDS. 2000 Jul 28;14(11):1591-600.

PMID:
10983646
15.

A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.

Arranz Caso JA, López JC, Santos I, Estrada V, Castilla V, Sanz J, Sanz J, Molina JP, Fernández Guerrero M, Górgolas M.

HIV Med. 2005 Sep;6(5):353-9. Erratum in: HIV Med. 2005 Nov;6(6):426.

16.

Treatment switch guided by HIV-1 genotyping in Brazil.

Tupinambás U, Ribeiro FA, Aleixo A, Greco D.

Braz J Infect Dis. 2006 Apr;10(2):82-8.

17.
18.

Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.

Eron JJ, Yetzer ES, Ruane PJ, Becker S, Sawyer GA, Fisher RL, Tolson JM, Shaefer MS.

AIDS. 2000 Apr 14;14(6):671-81. Erratum in: AIDS 2000 Jun 16;14(9):1295.

PMID:
10807190
19.

Ritonavir and saquinavir combination therapy for the treatment of HIV infection.

Cameron DW, Japour AJ, Xu Y, Hsu A, Mellors J, Farthing C, Cohen C, Poretz D, Markowitz M, Follansbee S, Angel JB, McMahon D, Ho D, Devanarayan V, Rode R, Salgo M, Kempf DJ, Granneman R, Leonard JM, Sun E.

AIDS. 1999 Feb 4;13(2):213-24.

PMID:
10202827
20.

Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.

Røge BT, Barfod TS, Kirk O, Katzenstein TL, Obel N, Nielsen H, Pedersen C, Mathiesen LR, Lundgren JD, Gerstoft J.

HIV Med. 2004 Sep;5(5):344-51.

Supplemental Content

Support Center